State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Laboratory Center, 159428Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, China.
159428First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820970688. doi: 10.1177/1533033820970688.
Minichromosome maintenance (MCM) proteins play an important role in replication and cell cycle progression. Even so, their expression and prognostic roles in cancer remain controversial.
To address this issue, the study investigated the roles of MCMs in the prognosis of GC by using ONCOMINE, GEPIA2, UALCAN, Cancer Cell Line Encyclopedia (CCLE), the Human Protein Atlas, Kaplan-Meier Plotter, cBioPortal, GeneMANIA, and DAVID databases.
Over expressions of mRNA and cell lines were found in all members of the MCM family, and MCMs were found to be significantly associated with pathological tumor grades in GC patients. Besides, higher mRNA expressions of MCM1/5/7 were found to be significantly associated with shorter overall survival (OS) and progression-free survival (FP) in GC patients, while higher mRNA expression of MCM4/6/9 were connected with favorable OS and FP. Moreover, a high mutation rate of MCMs (68%) was also observed in GC patients.
The results indicated that MCM1/5/7 were potential targets of precision therapy for patients with GC. And MCM4/6/9 were new biomarkers for the prognosis of GC. The results of the study will contribute to supplement the existing knowledge, and help to explore therapeutic targets and enhance the accuracy of prognosis for patients with GC.
微小染色体维持（MCM）蛋白在复制和细胞周期进展中起着重要作用。即便如此，它们在癌症中的表达和预后作用仍存在争议。
为了解决这个问题，该研究使用 ONCOMINE、GEPIA2、UALCAN、癌症细胞系百科全书（CCLE）、人类蛋白质图谱、Kaplan-Meier Plotter、cBioPortal、GeneMANIA 和 DAVID 数据库，研究了 MCM 在 GC 预后中的作用。
在 MCM 家族的所有成员中都发现了 mRNA 和细胞系的过度表达，并且 MCM 与 GC 患者的病理肿瘤分级显著相关。此外，在 GC 患者中，MCM1/5/7 的 mRNA 表达水平较高与总生存期（OS）和无进展生存期（FP）较短显著相关，而 MCM4/6/9 的 mRNA 表达水平较高与 OS 和 FP 较好相关。此外，还观察到 GC 患者的 MCM 突变率较高（68%）。
结果表明，MCM1/5/7 可能是 GC 患者精准治疗的潜在靶点。MCM4/6/9 是 GC 预后的新标志物。该研究的结果将有助于补充现有知识，帮助探索治疗靶点，并提高 GC 患者的预后准确性。
